AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

RecruitingNAAges 8 Years - 10 YearsAllShanghai Eye Disease Prevention and Treatment Cenโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL with different combinations of power and frequency.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Age: 8-10 years old 2. Low myopia: cycloplegic spherical equivalent refractions (SERs) range from -0.50 (inclusive) to -3.00 diopters (D) and astigmatism less than -2.5 D in either eye. 3. signed informed consent and was able to participate in the study Exclusion Criteria: 1. Secondary myopia, such as a history of retinopathy of prematurity or other neonatal diseases; syndromic myopia with a known genetic disorder or connective tissue disease, such as Stickler syndrome or Marfan syndrome 2. Strabismus or other binocular vision abnormalities 3. Cloudy refractive media: cloudy cornea, cataract or intraocular lens surgery 4. Eye diseases that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc. 5. History of refractive surgery, internal eye surgery, laser therapy, vitreous injection, etc. 6. diabetes, hypertension and other systemic disorders 7. History of use of retinal toxic drugs, such as hydroxychloroquine, etc. 8. Use of orthokeratology, atropine, multifocal frame glasses and other myopia control methods; children who are currently receiving atropine, orthokeratology, multifocal frame glasses and other myopia control treatment, can be enrolled after 2 weeks of treatment. 9. Other reasons considered unsuitable for inclusion by the study physician, including but not limited to other ocular and systemic disease abnormalities
๐Ÿ’Š

What it tests

  • Repeated Low-level Red-light
  • Red LED
๐Ÿ“

Where

1 site
Shanghai Eye Disease Prevention & Treatment Center
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy